Microgestin how much estrogen

Each pack contains:. Most side effects of Junel Fe and Microgestin Fe are mild and often go away after a few weeks.

Others may be more serious and can require medical care. If you're still struggling with any mild side effects after you've been on Junel Fe or Microgestin for three months, another birth control brand or method may be a better fit. Talk to your doctor about your options. Our doctors are available to reassess and write a new prescription at any time at no cost to you —thanks to our Complete Care plan.

If you experience any of the serious side effects above, contact a doctor immediately. We make getting birth control easy, affordable and way less of a hassle than it's ever been. Junel Fe and Microgestin Fe are both very affordable birth control options. Plus, how hormonal birth control might help relieve some of the symptoms of perimenopause. Get Junel Fe or Microgestin Fe. Gallbladder disease. Conditions aggravated by fluid retention; monitor. Evaluate significant changes in headaches, irregular uterine bleeding, amenorrhea, retinal vein thrombosis.

Monitor BP. Do regular complete physical exams. May need barrier contraception with Sunday starts or postpartum use see full labeling. Nursing mothers: not recommended.

Antagonized by hepatic enzyme inducing drugs eg, rifampin, griseofulvin, St. John's wort , possibly others. Absorption may be incomplete in cases of severe vomiting or diarrhea. If these symptoms occur, additional contraceptive measures should be taken. If vomiting occurs within 3 to 4 hours after administration, this can be regarded as a missed dose.

For multi-phasic products, explanation of tablet or capsule sequencing and different tablet or capsule colors may be needed. Contraceptive packs contain iron tablets or capsules. The iron tablets or capsules are included so that the daily dosage cycle can be continuous. This reduces the chance of missed doses. The iron-only doses are taken at the end of the cycle. OC administration instructions for patients: Instruct patient on risks and warnings associated with hormonal contraceptives.

Missing pills can cause spotting or light bleeding. The length of time required for using a second method of contraception after drug initiation is slightly different for each manufacturer. In general, a second, non-hormonal form of contraception should be used until active norethindrone acetate; ethinyl estradiol; ferrous fumarate tablets have been taken for at least 7 consecutive days.

Each manufacturer has slightly different recommendations for missed pills. Patients should be instructed to review the patient information leaflet that accompanies the prescription each time it is filled. General recommendations for missed OC doses: If one dose is missed, the patient should take it as soon as she remembers and then take the next pill at the regular time as usual.

It may be necessary to take 2 tablets or capsules in one day. Some manufacturers recommend that a second method of non-hormonal contraception be used for at least 7 days after restarting the pills. If two doses in a row are missed, 2 tablets or capsules should be taken on both the day the missed doses are remembered and the following day. The regular schedule should then be continued. A second method of non-hormonal contraception should be used for at least 7 days after restarting the pills.

If 3 or more doses in a row are missed, the patient should not take the missed pills. Recommendations for restarting the pills can be found in the patient information leaflet that accompanies the prescription each time it is filled. A second method of contraception should be used for at least 7 days after the pills are restarted. Chewable oral contraceptive OC tablets e. Instruct patient to drink a full glass 8 ounces of water immediately after swallowing the chewed tablet.

Contraceptive pack contains 28 tablets. The first 24 pills contain active hormones; the last 4 tablets contain iron. Use of norethindrone acetate; ethinyl estradiol; ferrous fumarate products, as with other contraceptive steroids, may result in clinical changes that influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins.

Specific laboratory test interference has not been reported. Norethindrone acetate; ethinyl estradiol; ferrous fumarate does not protect against human immunodeficiency virus HIV infection or other sexually transmitted disease. Conversely, patients with known HIV infection or acquired immunodeficiency syndrome AIDS should be aware that the use of this combined oral hormonal contraceptive COC will not prevent the transmission of HIV or other diseases to their partner s.

Surgery can increase the risk for thromboembolism from combined hormonal contraceptives. If feasible, discontinue norethindrone acetate; ethinyl estradiol; ferrous fumarate products at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of thromboembolism, and during and following any prolonged immobilization.

Because of the increased potential for embolic risk, combined oral contraceptives COCs containing norethindrone acetate; ethinyl estradiol are contraindicated in women who currently have diabetes mellitus and are over 35 years of age, diabetes mellitus with hypertension or with vascular disease or end-organ damage, or diabetes mellitus of greater than 20 years duration.

Patients with diabetes mellitus should be observed for changes in glucose tolerance when initiating or discontinuing estrogen therapy, since estrogen therapy may exacerbate diabetes. Altered glucose tolerance secondary to decreased insulin sensitivity has been reported. Women who are being treated for dyslipidemia should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of hyperlipidemia more difficult. Females with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.

Norethindrone acetate; ethinyl estradiol; ferrous fumarate is contraindicated in patients with migraine or other headache that is accompanied by focal neurological symptoms, such as aura, or women over age 35 with any migraine headaches. COCs may cause an exacerbation of migraine or a change in headache patterns and should be used with caution in women with migraine. Patients who complain of migraine with focal neurologic visual changes should be medically evaluated, and in some patients, such changes may indicate cerebrovascular events.

Consistent with potential thrombotic effects of combined oral hormonal contraceptives COCs , there have been clinical case reports of retinal thrombosis with COC use.

The COC should be discontinued if there is unexplained visual disturbance, partial or complete loss of vision, onset of proptosis or diplopia, papilledema, or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately. Estrogens can increase the curvature of the cornea; patients using contact lenses wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.

Norethindrone acetate; ethinyl estradiol; ferrous fumarate is contraindicated in patients with hypersensitivity to any of the product components. Ethinyl estradiol is generally contraindicated in patients who have a history of anaphylaxis or history of angioedema to the drug. Cases of both anaphylactic reactions and angioedema have been reported in patients taking estrogens.

Events have developed in minutes and have required emergency medical treatment. Exogenous estrogens may induce or exacerbate symptoms of angioedema, particularly in women with hereditary angioedema, which may be hormonally sensitive. Given the increased prevalence of hypercoagulable states in patients with systemic lupus erythematosus SLE in particular antiphospholipid antibodies and lupus anticoagulant and the risk factors for thromboembolism, consider risks vs.

Avoid COC use in SLE patients with a history of venous or arterial thrombosis or the presence of a hypercoagulable state. Combined hormonal oral contraceptive COC use has also been reported to induce, unmask, or exacerbate SLE; more data are needed. Discontinue norethindrone acetate; ethinyl estradiol; ferrous fumarate if pregnancy is detected; there is no reason to continue combined oral hormonal contraceptives COCs during pregnancy.

Epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects including cardiac anomalies and limb-reduction defects following exposure to COCs before conception or during early pregnancy.

For any patient who has missed two consecutive periods, pregnancy should be ruled out. If the patient has not adhered to the prescribed COC schedule, consider the possibility of pregnancy at the first missed period. Discontinue COC use if pregnancy is confirmed. Manufacturers recommend avoidance of combined hormonal oral contraceptives OCs if possible until a mother has completely weaned her child. Small amounts of oral contraceptive steroids estrogens and progestins have been identified in the milk of nursing mothers and a few reports of effects on the infant exist, including jaundice and breast enlargement.

Experts often recommend avoidance of estrogen-containing hormonal contraceptives, in the first 21 days postpartum due to maternal post-partum risks for thromboembolism following obstetric delivery, and the potential for COCs to interfere with the establishment of lactation. It is generally accepted that estrogen-containing combined hormonal contraceptives may be used after this period in healthy women without other risk factors; general monitoring of the infant for effects such as appetite changes, breast changes and proper weight gain and growth should occur.